

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5209535/kihyun-kim-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232 papers	4,339 citations	33 h-index	60 g-index
239 ext. papers	5,248 ext. citations	3.8 avg, IF	4.6 L-index

#	Paper	IF	Citations
232	Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 612-8	2.2	457
231	Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6027-32	2.2	254
230	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2007</b> , 110, 972-8	2.2	245
229	Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1402-8	7.5	136
228	Daratumumab plus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , <b>2018</b> , 103, 2088-2096	6.6	133
227	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , <b>2015</b> , 126, 746-56	2.2	122
226	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. <i>Annals of Hematology</i> , <b>2007</b> , 86, 493-8	3	114
225	Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 1356-64	4.7	109
224	Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 671-84	4.8	108
223	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 537-49	4.5	107
222	Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. <i>Genome Research</i> , <b>2018</b> , 28, 1217-1227	9.7	90
221	Primary pulmonary non-Hodgkin's lymphoma. <i>Japanese Journal of Clinical Oncology</i> , <b>2004</b> , 34, 510-4	2.8	83
220	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , <b>2020</b> , 34, 1875-1884 <sup>10.7</sup>	10.7	77
219	L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2004</b> , 36, 2180-95	5.6	68
218	Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. <i>Korean Journal of Internal Medicine</i> , <b>2015</b> , 30, 496-505	2.5	64
217	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 46-58	59.2	61
216	Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 751-6	7.1	60

215	Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. <i>American Journal of Hematology</i> , <b>2002</b> , 71, 75-9	7.1	60
214	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. <i>Blood</i> , <b>2009</b> , 113, 4309-18	2.2	55
213	Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8, 237-40		52
212	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 757-63	1.9	51
211	Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 334, 313-8	3.4	50
210	Aggressive natural killer cell leukemia: clinical features and treatment outcome. <i>Haematologica</i> , <b>2002</b> , 87, 1343-5	6.6	47
209	Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 463-70	4.7	46
208	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2361-2371	4.0	46
207	Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. <i>British Journal of Haematology</i> , <b>2005</b> , 131, 59-66	4.5	40
206	Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 446-52	7.1	39
205	Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 339-44	1.9	39
204	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , <b>2011</b> , 90, 1391-8	3	37
203	Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , <b>2006</b> , 85, 781-6	3	37
202	Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3250-4	12.9	37
201	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , <b>2010</b> , 92, 52-7	2.3	34
200	L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 93, 257-70	4.7	34
199	Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 103	22.4	33
198	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , <b>2007</b> , 31, 359-64	2.7	31

197	A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. <i>International Journal of Hematology</i> , <b>2006</b> , 83, 309-13	2.3	30
196	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). <i>Blood</i> , <b>2019</b> , 134, 139-139	2.2	29
195	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , <b>2016</b> , 73, 496-505	18.9	28
194	Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , <b>2009</b> , 122, 200-10	2.7	27
193	Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , <b>2009</b> , 88, 111-9	3	27
192	Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis?. <i>Acta Haematologica</i> , <b>2008</b> , 120, 199-206	2.7	26
191	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , <b>2016</b> , 95, 325-35	3	25
190	Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 716-22	1.9	25
189	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	24
188	Cardiac amyloidosis without increased left ventricular wall thickness. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 781-9	6.4	24
187	Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 353-7	2.8	24
186	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1280-1286	7.1	23
185	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. <i>Annals of Hematology</i> , <b>2010</b> , 89, 201-6	3	23
184	Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 935-944	12.9	23
183	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. <i>Cellular Signalling</i> , <b>2005</b> , 17, 111-9	4.9	22
182	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2019</b> , 134, 1866-1866	2.2	21
181	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 37-41	7.1	20
180	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , <b>2015</b> , 35, 2363-9	7.9	19

179	Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. <i>Oncology</i> , <b>2004</b> , 66, 32-7	3.6	19
178	Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma. <i>BioMed Research International</i> , <b>2014</b> , 2014, 437852	3	18
177	Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. <i>Acta Haematologica</i> , <b>2014</b> , 131, 193-9	2.7	18
176	Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , <b>2007</b> , 258, 90-7	9.9	18
175	Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. <i>Anticancer Research</i> , <b>2015</b> , 35, 3081-9	2.3	18
174	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2014</b> , 21, 261-6	2.7	17
173	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , <b>2009</b> , 88, 1099-106	3	17
172	Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 205-13	1.9	17
171	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , <b>2006</b> , 85, 285-90	3	17
170	New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2006</b> , 12, 837-44	4.7	17
169	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 368-75	4.3	16
168	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 42803-12	3.3	16
167	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1353-61	3	15
166	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , <b>2011</b> , 93, 383-388	2.3	15
165	Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. <i>European Journal of Haematology</i> , <b>2009</b> , 83, 108-18	3.8	15
164	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. <i>Annals of Hematology</i> , <b>2010</b> , 89, 905-12	3	15
163	The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 227-35	2	14
162	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , <b>2016</b> , 16, 613	4.8	14

161	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1253-9	1.9	14
160	Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2002</b> , 25, 354-7	2.7	14
159	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. <i>Annals of Hematology</i> , <b>2012</b> , 91, 249-56	3	13
158	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. <i>European Journal of Haematology</i> , <b>2007</b> , 79, 287-91	3.8	13
157	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , <b>2017</b> , 8, 79517-79526	3.3	13
156	Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. <i>Annals of Hematology</i> , <b>2014</b> , 93, 113-21	3	12
155	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , <b>2013</b> , 37, 1070-6	2.7	12
154	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , <b>2017</b> , 36, 67-71	4.8	12
153	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2010</b> , 197, 117-21		12
152	Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of Korean all-ages group and Western younger age group. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 580-6		12
151	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	12
150	Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 743-749	4.5	11
149	Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis. <i>Scientific Reports</i> , <b>2019</b> , 9, 7746	4.9	10
148	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). <i>Annals of Hematology</i> , <b>2012</b> , 91, 100-07	3	10
147	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2018</b> , 132, 1996-1996	2.2	10
146	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , <b>2018</b> , 140, 146-156	2.7	10
145	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 967-976	4.4	9
144	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2305-2317	1.9	9



143	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 923-929	4.7	9
142	Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 52-5	7.1	9
141	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. <i>Annals of Hematology</i> , <b>2010</b> , 89, 1011-8	3	9
140	Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , <b>2006</b> , 30, 1253-8	2.7	9
139	A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. <i>Blood</i> , <b>2015</b> , 126, 4239-4239	2.2	9
138	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , <b>2015</b> , 76, 636-43	2.3	8
137	Prognostic Value of Baseline F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study. <i>Korean Journal of Radiology</i> , <b>2018</b> , 19, 481-488	6.9	8
136	Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , <b>2006</b> , 77, 304-8	3.8	8
135	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , <b>2021</b> ,	10.7	8
134	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , <b>2019</b> , 49, 92-95	2.8	8
133	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , <b>2019</b> , 98, 941-949	3	7
132	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 707-710	4.5	7
131	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1110-8	1.9	7
130	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , <b>2020</b> , 136, 48-50	2.2	7
129	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , <b>2020</b> , 20, 803	4.8	7
128	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , <b>2019</b> , 109, 79-90	2.3	7
127	Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience. <i>Annals of Laboratory Medicine</i> , <b>2018</b> , 38, 196-203	3.1	7
126	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , <b>2014</b> , 34, 4299-306	2.3	7

125	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1312-1319	4.7	6
124	Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer. <i>Journal of Infection</i> , <b>2016</b> , 72, 233-9	18.9	6
123	Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. <i>Acta Haematologica</i> , <b>2014</b> , 132, 226-32	2.7	6
122	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 53-54	2.2	6
121	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). <i>American Journal of Hematology</i> , <b>2020</b> , 95, 413-421	7.1	6
120	Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e13089	2.4	5
119	Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma. <i>Journal of Clinical Laboratory Analysis</i> , <b>2015</b> , 29, 505-10	3	5
118	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003091	11.6	5
117	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , <b>2019</b> , 34, 579-588	3.2	5
116	Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2013</b> , 20, 204-11	2.7	5
115	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , <b>2008</b> , 25, 447-50	3.7	5
114	Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8546-8546	2.2	5
113	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. <i>International Journal of Heart Failure</i> , <b>2020</b> , 2, 231	1.3	5
112	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. <i>Oncotarget</i> , <b>2016</b> , 7, 47127-47133	3.3	5
111	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , <b>2021</b> , 35, 1797-1802	10.7	5
110	Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis. <i>Journal of Cancer</i> , <b>2021</b> , 12, 2825-2834	4.5	5
109	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , <b>2017</b> , 6, 100-108	4.8	4
108	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 83	7	4



107	A case of Fanconi syndrome accompanied by crystal depositions in tubular cells in a patient with multiple myeloma. <i>Kidney Research and Clinical Practice</i> , <b>2014</b> , 33, 112-5	3.6	4
106	Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. <i>BioMed Research International</i> , <b>2014</b> , 2014, 253243	3	4
105	Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 937-43	1.9	4
104	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. <i>Blood</i> , <b>2013</b> , 122, 3189-3189	2.2	4
103	Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. <i>Oncotarget</i> , <b>2016</b> , 7, 68350-68359	3.3	4
102	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 37605-37618	3.3	4
101	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , <b>2020</b> , 99, 309-319	3	4
100	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 111	7	3
99	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , <b>2020</b> , 103, 1630-1636	3.1	3
98	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2714-2721	1.9	3
97	99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: Potential clinical implications. <i>Medicine (United States)</i> , <b>2020</b> , 99, e18905	1.8	3
96	Development and Validation of Mass Spectrometry-Based Targeted Analysis for Amyloid Proteins. <i>Proteomics - Clinical Applications</i> , <b>2018</b> , 12, e1700106	3.1	3
95	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , <b>2017</b> , 47, 995-1001	2.8	3
94	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , <b>2015</b> , 50, 7-18	1.4	3
93	Spinal cord compression in multiple myeloma: a single center experience. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2395-7	1.9	3
92	Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma. <i>Blood Research</i> , <b>2013</b> , 48, 233-4	1.4	3
91	Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. <i>Journal of Korean Medical Science</i> , <b>2013</b> , 28, 80-6	4.7	3
90	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 101-112	4.5	3

89	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE <sup>®</sup> , Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.. <i>Blood</i> , <b>2007</b> , 110, 952-952	2.2	3
88	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. <i>Blood</i> , <b>2015</b> , 126, 4240-4240	2.2	3
87	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , <b>2016</b> , 51, 193-199	1.4	3
86	Prognostic values of novel biomarkers in patients with AL amyloidosis. <i>Scientific Reports</i> , <b>2019</b> , 9, 12200	4.9	2
85	Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report. <i>Case Reports in Nephrology and Dialysis</i> , <b>2015</b> , 5, 180-6	1.3	2
84	Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 118-26	2	2
83	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 190	7	2
82	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , <b>2015</b> , 30, 675-83	2.5	2
81	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 784-788	4.5	2
80	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , <b>2016</b> , 95, 911-9	3	2
79	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1065-1077	3	2
78	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 2051-2059	4.4	1
77	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. <i>Blood</i> , <b>2020</b> , 136, 11-11	2.2	1
76	A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , <b>2004</b> , 104, 3162-3162	2.2	1
75	Single and Tandem Autologous Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: A Korean Multicenter Retrospective Study.. <i>Blood</i> , <b>2007</b> , 110, 5132-5132	2.2	1
74	A Multicenter Comparison of Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation with Tandem Autologous Stem Cell Transplantation in Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 940-940	2.2	1
73	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.. <i>Blood</i> , <b>2008</b> , 112, 3330-3330	2.2	1
72	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. <i>Blood</i> , <b>2008</b> , 112, 5184-5184	2.2	1

71	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , <b>2009</b> , 114, 1792-1792	2.2	1
70	Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , <b>2016</b> , 128, 2130-2130	2.2	1
69	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8097-8097	2.2	1
68	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20698-e20698	2.2	1
67	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 1110-1110	2.2	1
66	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e97-e104	2	1
65	Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Infections in Tertiary Care Setting?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
64	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, 668-678	2.5	1
63	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , <b>2021</b> , 36, 737-749	3.2	1
62	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 81-91	2.3	1
61	Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
60	Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.. <i>Annals of Laboratory Medicine</i> , <b>2022</b> , 42, 558-565	3.1	1
59	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , <b>2020</b> , 112, 84-95	2.3	0
58	tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method. <i>Analytical Chemistry</i> , <b>2021</b> , 93, 14088-14098	4.09	0
57	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , <b>2020</b> , 40, 88-91	3.1	0
56	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 4969-4977	3.9	0
55	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. <i>International Journal of Hematology</i> , <b>2021</b> , 114, 653-663	2.3	0
54	A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model. <i>Immunology Letters</i> , <b>2019</b> , 216, 21-27	4.1	

- 53 Generation and Qualification of Functionally Active Leukemia-derived DCs from Malignant Blasts in Acute Leukemia. *The Korean Journal of Hematology*, **2007**, 42, 264
- 52 Interferon-Resistance can be reversed by inhibition of IFN-Induced COX-2 expression potentially via STAT1 activation in A549 cells. *Oncology Reports*, **2006**, 15, 1541 3.5
- 51 Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study. *Blood*, **2020**, 136, 14-14 2.2
- 50 The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. *Blood*, **2020**, 136, 30-31 2.2
- 49 Exploration of the Appropriate NT-Probnp Level for AL Amyloidosis Staging. *Blood*, **2021**, 138, 3777-3777 2.2
- 48 Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders. *Korean Journal of Medicine*, **2021**, 96, 371-381 0.5
- 47 Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. *British Journal of Haematology*, **2021**, 4.5
- 46 CHOP Followed by Radiotherapy for Localized Aggressive Primary Gastric Lymphoma: Results of a Multi Center Phase II Study.. *Blood*, **2004**, 104, 3306-3306 2.2
- 45 Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. *Blood*, **2005**, 106, 5415-5415 2.2
- 44 A Comparison of 3 Staging Systems for the Outcome Following Autologous Stem Cell Transplantation (ASCT) in Patients with Multiple Myeloma (MM).. *Blood*, **2005**, 106, 5479-5479 2.2
- 43 Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. *Blood*, **2005**, 106, 1491-1491 2.2
- 42 Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. *Blood*, **2005**, 106, 3500-3500 2.2
- 41 Intestinal Marginal Zone B-Cell Lymphoma of MALT Type: Clinical Manifestation and Outcome of a Rare Disease.. *Blood*, **2006**, 108, 4742-4742 2.2
- 40 Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. *Blood*, **2006**, 108, 4670-4670 2.2
- 39 Velcade<sup>®</sup>, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.. *Blood*, **2007**, 110, 4831-4831 2.2
- 38 Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. *Blood*, **2007**, 110, 1361-1361 2.2
- 37 The Optimal Processing Time of Adipose-Derived Mesenchymal Stem Cell after Lipoaspiration.. *Blood*, **2007**, 110, 4107-4107 2.2
- 36 Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. *Blood*, **2007**, 110, 4843-4843 2.2

35	Prediction of Survival in Patients with Myelodysplastic Syndrome According to WHO Classification-Based Prognostic Scoring System (WPSS).. <i>Blood</i> , <b>2007</b> , 110, 4617-4617	2.2
34	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. <i>Blood</i> , <b>2018</b> , 132, 3347-3347	2.2
33	Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center. <i>Blood</i> , <b>2019</b> , 134, 5585-5585	2.2
32	The Clinical Impact of Thalidomide Maintenance on Progression Free Survival and Postrelapse Survival after Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple myeloma. <i>Blood</i> , <b>2014</b> , 124, 3975-3975	2.2
31	The Prognostic Impact of Inflammatory Factors for Survival in Patients with Newly Diagnosed Multiple Myeloma Who Were Treated with Thalidomide Containing Induction Chemotherapy Underwent Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 5896-5896	2.2
30	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , <b>2015</b> , 126, 1904-1904	2.2
29	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , <b>2015</b> , 126, 5160-5160	2.2
28	Clinical utility of comprehensive approach to detect genetic abnormalities in multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8034-8034	2.2
27	A Prognostic Scoring System for Patients with Multiple Myeloma Who Were Classified Stage II By Revised International Staging System. <i>Blood</i> , <b>2016</b> , 128, 3284-3284	2.2
26	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , <b>2016</b> , 128, 4414-4414	2.2
25	Patterns of Treatment Failure in Systemic Light Chain Amyloidosis with Long-Term Survival after Chemotherapy. <i>Blood</i> , <b>2016</b> , 128, 2132-2132	2.2
24	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , <b>2016</b> , 128, 4445-4445	2.2
23	Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. <i>Blood</i> , <b>2016</b> , 128, 4650-4650 <sup>2.2</sup>	2.2
22	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 5683-5683	2.2
21	Clinical manifestation and prognostic features of extramedullary plasmacytomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e19516-e19516	2.2
20	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. <i>Blood</i> , <b>2008</b> , 112, 4219-4219	2.2
19	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. <i>Blood</i> , <b>2008</b> , 112, 4109-4109	2.2
18	Velcade <sup>®</sup> , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. <i>Blood</i> , <b>2008</b> , 112, 2785-2785	2.2



- 17 Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. *Blood*, **2009**, 114, 4661-4661 2.2
- 16 First Asia-Pacific Co-Operative Multicenter Multiple Myeloma Clinical Trial: Preliminary Results of the BtZ/VD/DAZZLE Study.. *Blood*, **2009**, 114, 4940-4940 2.2
- 15 Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. *Blood*, **2009**, 114, 4881-4881 2.2
- 14 Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. *Blood*, **2009**, 114, 4298-4298 2.2
- 13 Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. *Blood*, **2010**, 116, 4371-4371 2.2
- 12 Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. *Blood*, **2011**, 118, 1990-1990 2.2
- 11 Early Response to Bortezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. *Blood*, **2011**, 118, 5138-5138 2.2
- 10 Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC,. *Blood*, **2011**, 118, 3563-3563 2.2
- 9 Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis.. *Blood*, **2012**, 120, 3106-3106 2.2
- 8 Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. *Blood*, **2013**, 122, 5379-5379 2.2
- 7 Post-Transplant Immune Monitoring In Patients Receiving Allogeneic Stem Cell Transplantation. *Blood*, **2013**, 122, 5486-5486 2.2
- 6 First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism. *Annals of Laboratory Medicine*, **2019**, 39, 96-98 3.1
- 5 Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. *Current Problems in Cancer*, **2021**, 46, 100786 2.3
- 4 Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. *Current Problems in Cancer*, **2021**, 46, 100788 2.3
- 3 Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.. *Annals of Hematology*, **2022**, 101, 1217 3
- 2 Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).. *International Journal of Hematology*, **2022**, 1 2.3
- 1 Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, 1-7 2.7